Literature DB >> 1524699

Drug interactions with quinolone antibacterials.

J R Brouwers1.   

Abstract

The quinolone antibacterials are prone to many interactions with other drugs. Quinolone absorption is markedly reduced with antacids containing aluminium, magnesium and/or calcium and therapeutic failure may result. Other metallic ion-containing drugs, such as sucralfate, iron salts, and zinc salts, can also reduce absorption. Some of the newer quinolones inhibit the cytochrome P450 system, e.g. enoxacin, pefloxacin and ciprofloxacin. The toxicity of drugs that are metabolised by the cytochrome P450 system is enhanced by concomitant use of some quinolones. Ciprofloxacin, enoxacin and pefloxacin can increase theophylline concentrations to toxic values. The pharmacokinetics of warfarin and cyclosporin are unaffected. Ofloxacin, fleroxacin and temafloxacin have a low inhibitory effect on the cytochrome P450 system and a low interaction potential may result. The affinity of quinolones for the gamma-aminobutyric acid (GABA) receptor may induce CNS adverse effects; these effects are enhanced by some nonsteroidal anti-inflammatory drugs (NSAIDs).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1524699     DOI: 10.2165/00002018-199207040-00003

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  58 in total

1.  Ciprofloxacin and warfarin interaction.

Authors:  D Linville; C Emory; L Graves
Journal:  Am J Med       Date:  1991-06       Impact factor: 4.965

2.  Effect of staggered dose of calcium on the bioavailability of ciprofloxacin.

Authors:  B M Lomaestro; G R Bailie
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

3.  Clinical and chemical interactions between iron preparations and ciprofloxacin.

Authors:  M Kara; B B Hasinoff; D W McKay; N R Campbell
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

4.  Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis.

Authors:  T A Golper; A I Hartstein; V H Morthland; J M Christensen
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

5.  The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine.

Authors:  B E Bleske; P L Carver; T M Annesley; J R Bleske; F Morady
Journal:  J Clin Pharmacol       Date:  1990-10       Impact factor: 3.126

6.  Cyclosporine (cyclosporin A) pharmacokinetics in renal transplant patients receiving ciprofloxacin.

Authors:  J Lang; J Finaz de Villaine; R Garraffo; J L Touraine
Journal:  Am J Med       Date:  1989-11-30       Impact factor: 4.965

7.  Ciprofloxacin-caffeine: a drug interaction established using in vivo and in vitro investigations.

Authors:  S Harder; U Fuhr; A H Staib; T Wolff
Journal:  Am J Med       Date:  1989-11-30       Impact factor: 4.965

Review 8.  Inhibition of drug metabolism by quinolone antibiotics.

Authors:  D J Edwards; S K Bowles; C K Svensson; M J Rybak
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

9.  4-quinolones inhibit biotransformation of caffeine.

Authors:  S Harder; A H Staib; C Beer; A Papenburg; W Stille; P M Shah
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 10.  Drug-drug interactions with ciprofloxacin and other fluoroquinolones.

Authors:  R E Polk
Journal:  Am J Med       Date:  1989-11-30       Impact factor: 4.965

View more
  13 in total

Review 1.  Fluoroquinolones: use of clinical data to aid formulary choice by the system of objective judgement analysis (SOJA) method.

Authors:  R Janknegt
Journal:  Pharmacoeconomics       Date:  1994-07       Impact factor: 4.981

2.  Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions.

Authors:  H Bohets; K Lavrijsen; J Hendrickx; J van Houdt; V van Genechten; P Verboven; W Meuldermans; J Heykants
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

Review 3.  Drug interactions with cisapride: clinical implications.

Authors:  E L Michalets; C R Williams
Journal:  Clin Pharmacokinet       Date:  2000-07       Impact factor: 6.447

4.  Theophylline and warfarin interaction studies with grepafloxacin.

Authors:  C Efthymiopoulos; S L Bramer; A Maroli; B Blum
Journal:  Clin Pharmacokinet       Date:  1997       Impact factor: 6.447

Review 5.  Fluoroquinolones: interaction profile during enteral absorption.

Authors:  K M Deppermann; H Lode
Journal:  Drugs       Date:  1993       Impact factor: 9.546

6.  Double-blind, comparative study of rufloxacin once daily versus amoxicillin three times a day in treatment of outpatients with exacerbations of chronic bronchitis.

Authors:  W Klietmann; M Cesana; R K Rondel; J Focht
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

7.  Effect of bismuth subsalicylate on ciprofloxacin bioavailability.

Authors:  L Rambout; J Sahai; K Gallicano; L Oliveras; G Garber
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

Review 8.  Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.

Authors:  K L Goa; H M Bryson; A Markham
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

9.  Effects of fish CYP inducers on difloxacin N-demethylation in kidney cell of Chinese idle (Ctenopharyngodon idellus).

Authors:  Ling Zhi Yu; Xian Le Yang; Xiang Ling Wang; Wen Juan Yu; Kun Hu
Journal:  Fish Physiol Biochem       Date:  2009-08-15       Impact factor: 2.794

Review 10.  Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.

Authors:  J R Brouwers; P A de Smet
Journal:  Clin Pharmacokinet       Date:  1994-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.